Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) – Which System Can Optimise Surgical Therapy?

Digitale Vollfeldmammografie (FFDM), CMOS-Technologie, Specimen Radiography System (SRS) versus Tomosynthese (DBT) – welches System optimiert die operative Therapie?

Authors

Affiliations
The affiliations are listed at the end of the article

Key words
Breast
mammography
breast cancer
breast malignancy

Schlüsselwörter
Mamma
Mammografie
Mammakarzinom
Mammamalignom

Abstract
Aim: This prospective clinical study aimed to evaluate whether it would be possible to reduce the rate of re-excisions using CMOS technology, a specimen radiography system (SRS) or digital breast tomosynthesis (DBT) compared to a conventional full field digital mammography (FFDM) system.

Material and Method: Between 12/2012 and 2/2013 50 patients were diagnosed with invasive breast cancer (BI-RADS™ 5). After histological verification, all patients underwent breast-conserving therapy with intraoperative imaging using 4 different systems and differing magnifications: 1. Inspiration™ (Siemens, Erlangen, Germany), amorphous selenium, tungsten source, focus 0.1 mm, resolution 85 µm pixel pitch, 8 lp/mm; 2. BioVision™ (Biopics, Tucson, AZ, USA), CMOS technology, photodiode array, flat panel, tungsten source, focus 0.05, resolution 50 µm pixel pitch, 12 lp/mm; 3. the Trident™ specimen radiography system (SRS) (Hologic, Bedford, MA, USA), amorphous selenium, tungsten source, focus 0.05, resolution 70 µm pixel pitch, 7.1 lp/mm; 4. tomosynthesis (Siemens, Erlangen, Germany), amorphous selenium, tungsten source, focus 0.1 mm, resolution 85 µm pixel pitch, 8 lp/mm, angular range 50 degrees, 25 projections, scan time > 20 s, geometry: uniform scanning, reconstruction: filtered back projection. The 600 radiographs were prospectively shown to 3 radiologists.

Results: Of the 50 patients with histologically proven breast cancer (BI-RADS™ 6), 39 patients required no further surgical therapy (re-excision) after breast-conserving surgery. A retrospective analysis (n = 11) showed a significant (p < 0.05) increase of sensitivity with the BioVision™, the Trident™ and tomosynthesis compared to the Inspiration™ at a magnification of 1.0:2.0 or 1.0:1.0 (tomosynthesis) (2.6, 3.3 or 3.6%), i.e. re-

Zusammenfassung
Ziel: Prospektive Untersuchung, ob mit Hilfe der CMOS-Technologie, dem Specimen Radiography System bzw. der digitalen Brusttomosynthese (DBT) im Vergleich mit einem herkömmlichen FFDM-System eine Senkung der Rate an Reexzisionen möglich ist.

Material und Methode: In der Zeit von 12/2012 bis 2/2013 wurde bei 50 Patientinnen ein invasives Mammakarzinom (BI-RADS™ 5) diagnostiziert. Nach histologischer Sicherung erfolgte die brusterhaltende Therapie mit intraoperativem Präparatendendogramm mit 4 unterschiedlichen Systemen und Vergrößerungen: 1. Inspiration™ (Siemens, Erlangen, Deutschland), amorphes Selenium, W-Anode, Fokus 0,1 mm, Ortsauflösung 85 µm Pixelpitch, 8 lp/mm. 2. BioVision™ (Biopics, Tucson, AZ, USA), CMOS-Technologie, Photodioden Array, Flat Panel, W-Anode, Fokus 0,05, Ortsauflösung 50 µm Pixelpitch, 12 lp/mm. 3. Trident™ (Hologic, Bedford, MA, USA), Specimen Radiography System (SRS System), amorphes Selenium, W-Anode, Fokus 0,05, Ortsauflösung 70 µm Pixelpitch, 7,1 lp/mm. 4. Tomosynthese (Siemens, Erlangen, Deutschland), amorphes Selenium, W-Anode, Fokus 0,1 mm, Ortsauflösung 85 µm Pixelpitch, 8 lp/mm, Winkelbereich 50 Grad, 25 Projektionen, Scandauer > 20 s, Geometrie: gleichförmige Abtastung, Rekonstruktion: gefilterte Rückprojektion. Die jeweils 600 Präparatendendogramme wurden prospektiv 3 Radiologen auf einem Be- fundungssensor präsentiert.

Ergebnisse: Bei den 50 Patientinnen mit histologisch gesichertem Mammakarzinom (BI-RADS™ 6) war bei 39 Patientinnen nach erfolgter brusterhaltender Therapie keine weitere operative Therapie (Reexzision) indiziert. Die retrospektive Analyse (n = 11) ergab eine signifikante (p < 0.05) Steigerung der Sensitivität des BioVision™-, des Trident™-Systems und der Tomosynthese gegenüber dem Inspiration™ bei einer
excision would not have been necessary in 2, 3 or 4 patients, respectively, compared to findings obtained with a standard magnification of 1.0: 1.0.

**Conclusion:** The sensitivity of the BioVision™, the Trident™ and tomosynthesis was significantly (p < 0.05) higher and the rate of re-excisions was reduced compared to FFDM using a conventional detector at a magnification of 2.0 but without zooming.

**Introduction**

The risk of a woman developing breast cancer at some stage in her life is approximately 10%. This makes breast cancer the most common malignant growth in women and the most common cause of death for women between the ages of 35 and 55. In Germany, 55,000 women develop breast cancer every year and 20,000 die of it. The individual prognosis for patients with breast cancer depends on the extent of micrometastasis and spread of disease at the time of diagnosis and therapy [1–7]. Both the European Guidelines and the S3 Guidelines state that at least 70% of all malignant breast lesions (BI-RADS™ 5) should be histologically verified preoperatively – the target figure is 90% [8–11]. The thinking behind this is that only a single surgical intervention will be necessary after a detailed preoperative workup of a lesion diagnosed as a malignant process. In addition, all non-palpable breast lesions need to be marked (e.g. placement of a guide wire) prior to surgery [8–11].

Intraoperative radiography is the method of choice to assess the completeness of resection. Proposed approaches include transporting a resected specimen in a suitable container from the operating room to the radiology department for direct radiological examination [8–11] or, better yet, carrying out digital radiography intraoperatively directly in the operating room (2 planes). The surgeon and the pathologist can then either view the digital radiographs on film (analog/digital) or, more efficiently, via PACS. In the literature, the re-excision rate for breast cancer after primary breast-conserving therapy (BCT) to treat breast cancer previously verified histologically by B5 and therefore BI-RADS™ 6) is between 10 and 57%, depending on the defined safety margin [12, 13].

The aim of our prospective study was to evaluate whether the re-excision rate after histologically verified invasive breast cancer and subsequent breast-conserving therapy with wire localization could be reduced using CMOS technology (BioVision™; Bioptics, Tucson, AZ, USA), the Trident™ specimen radiography system (SRS) (Hologic, Bedford, MA, USA) and tomosynthesis (Siemens) compared to a conventional full field digital mammography system (Inspiration™, Siemens [standard]), using different magnifications.

**Material and Methods**

Between 12/2012 and 2/2013 a total of 50 patients were diagnosed with invasive breast cancer (BI-RADS™ 5) using complementary diagnostics (clinical examination, mammography, sonography, MRT). Patient age ranged between 21 and 84 years (mean: 62 years). Lesion sizes ranged from 4 to 17 mm (median: 13 mm), depending on the imaging method used. In accordance with the European Guidelines and the S3 Guidelines [8–11] ultrasound-guided punch biopsy or stereotactic vacuum-assisted biopsy was done preoperatively in all patients with histological findings classified as B5, which were then diagnosed as BI-RADS™ 6. As none of the cases had multifocal or multicentric lesions and the maximum diameter was less than 2.0 cm, in accordance with the S3 Guidelines none of the patients underwent primary neoadjuvant chemotherapy [10, 11].

After histological classification of the lesion as B5 (diagnostic evaluation: BI-RADS™ 6), all patients had ultrasound-guided or stereotactic wire localization preoperatively, depending on the primary method used for histological verification of the findings [8–11]. The lesions could be successfully localized at the first attempt in 46 patients, after the second attempt in 3 patients and after the third attempt in 1 patient. Breast-conserving therapy with sentinel lymph node biopsy (identified using patent blue and technetium-99m) was performed. This resected specimen was sutured marked (for orientation, 3 planes). The specimen was examined radiologically without compression with the wire still left in place [14] using 4 different systems (Inspiration™ [System 1]: 2 planes, standard; BioVision™ [System 2]: 2 planes; Trident™ [System 3]: 2 planes; tomosynthesis [System 4]: 1 plane) and AEC (Automatic Exposure Control) ( Table 1):

1. Inspiration™ (Siemens, Erlangen, Germany), amorphous selenium, tungsten source, focus 0.1 mm, resolution 85 µm pixel pitch, 8 lp/mm.
2. BioVision™ (Bioptics, Tucson, AZ, USA), CMOS technology, photodiode array, flat panel, tungsten source, focus 0.05, resolution 50 µm pixel pitch, 12 lp/mm.
3. Trident™ (Hologic, Bedford, MA, USA), a specimen radiography system (SRS), amorphous selenium, tungsten source, focus 0.05, resolution 70 µm pixel pitch, 7.1 lp/mm.
4. Tomosynthesis (Siemens, Erlangen, Germany), amorphous selenium, tungsten source, focus 0.1 mm, resolution 85 µm pixel pitch, 8 lp/mm, angular range 50 degrees, 25 projections, scan time > 20 s, geometry: uniform scanning, reconstruction: filtered back projection.

BioVision™ (CMOS technology, System 2) and Trident™ (specimen radiography system [SRS], System 3) are digital systems used exclusively for intraoperative radiography. On completion of the invasive procedure, all specimens were x-rayed again without compression according to the capabilities of the different system systems, using the following magnifications:

- 1.0: 1.0; 1.0: 1.5; 1.0: 1.8 with 26–28 kV (Inspiration™)
- 1.0: 1.0; 1.0: 1.4; 1.0: 2.0 with 26–28 kV (BioVision™)
- 1.0: 1.0; 1.0: 1.5; 1.0: 2.0 with 26–28 kV (Trident™)
- 1.0: 1.0; 1.0: 1.0; 1.0: 1.0 with 26–28 kV (tomosynthesis)
The radiographs (digital full field mammography: Inspiration™ [2 planes] = standard; BioVision™ [2 planes]; Trident™ [2 planes]; tomosynthesis [1 plane, 25 projections, dynamic cine mode]) obtained from a total of 50 specimens resected during breast-conserving surgery were prospectively shown intraoperatively on a diagnostic monitor to 3 radiologists with varying degrees of experience of digital mammography, i.e. radiologists were shown a total of 600 specimen radiographs. The diagnostic findings [lesion present with sufficient margin of safety [1.0 cm] on all 3 planes of the specimen radiograph [2 planes or 25 projections] or not] [10, 11] was then correlated with the final comprehensive histological diagnosis. All of the radiologists knew that all specimen radiographs showed a malignancy.

### Results

Of the 50 patients with histologically proven breast cancer (BIRADS™ 6), 39 patients required no further surgical intervention (re-excision) after breast-conserving therapy, as confirmed directly by radiographs made (intraoperatively) during the primary surgical intervention (Inspiration™ 2 planes, magnification 1.0:1.0, System 1 [standard]).

The final histopathologic diagnosis for 11 operated patients (re-excision) showed incomplete resection during primary surgery in 2 patients and a safety margin < 1.0 cm in 3 patients, i.e. no residual tumor detectable. This means that, based on the final histological diagnosis, the procedures were complete 39 times (98.0%) and incomplete 11 times (22.0%).

### Table 1  Basic technical characteristics of the different systems used for intraoperative radiography (Inspiration™ [System No. 1]; BioVision™ [System No. 2]; Trident™ [System No. 3]); tomosynthesis (System No. 4) additionally offers the possibility to view projection images in dynamic cine mode using an angular range of 50 degrees for 25 projections, a scan time of > 20 s, a uniform scanning geometry and filtered back projection for reconstruction.

<table>
<thead>
<tr>
<th>System No. 1: Inspiration™</th>
<th>System No. 2: BioVision™</th>
<th>System No. 3: Trident™</th>
<th>System No. 4: tomosynthesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Siemens</td>
<td>Hologic</td>
<td>Siemens</td>
</tr>
<tr>
<td>Anode</td>
<td>molybdenum, tungsten</td>
<td>tungsten</td>
<td>molybdenum, rhodium</td>
</tr>
<tr>
<td>Filter</td>
<td>molybdenum, rhodium</td>
<td>beryllium</td>
<td>molybdenum, rhodium</td>
</tr>
<tr>
<td>Anti-scatter radiation grid</td>
<td>linear</td>
<td>no</td>
<td>linear</td>
</tr>
<tr>
<td>Conversion material</td>
<td>semiconductor a-Se</td>
<td>photon conversion material: Gd202S: Tb (terbium-doped gadolinium oxyysulfide) phosphorous</td>
<td>semiconductor a-Se</td>
</tr>
<tr>
<td>Selection process</td>
<td>thin-film transistors</td>
<td>progressive line-scan selection</td>
<td>thin-film transistors</td>
</tr>
<tr>
<td>Pixel size</td>
<td>85 µm</td>
<td>70 µm</td>
<td>85 µm</td>
</tr>
<tr>
<td>Resolution (Nyquist frequency)</td>
<td>8 lp/mm</td>
<td>7.1 lp/mm</td>
<td>8 lp/mm</td>
</tr>
<tr>
<td>Field size</td>
<td>24 × 30 cm²</td>
<td>14 × 12 cm²</td>
<td>24 × 30 cm²</td>
</tr>
</tbody>
</table>

### Table 2  Sensitivity and specificity of the 3 systems (System No. 1: Inspiration™, System No. 2: BioVision™, System No. 3: Trident™, and System No. 4: tomosynthesis) as determined by 3 different radiologists who undertook a prospective evaluation of a total of 600 specimen radiographs/projection images (cine mode) of 50 patients with a malignancy (50 malignant lesions in total).

<table>
<thead>
<tr>
<th>Magnification</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0:1.0 (No. 1)</td>
<td>System No. 1: Inspiration™ (50 µm)</td>
<td>System No. 2: BioVision™ (50 µm)</td>
</tr>
<tr>
<td>Radiologist 1: 78.0</td>
<td>79.0</td>
<td>79.0</td>
</tr>
<tr>
<td>Radiologist 2: 79.0</td>
<td>78.0</td>
<td>78.0</td>
</tr>
<tr>
<td>Radiologist 3: 78.0</td>
<td>79.0</td>
<td>79.0</td>
</tr>
<tr>
<td>Mean: 78.3</td>
<td>78.6</td>
<td>78.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Magnification</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0:1.5 (No. 1)</td>
<td>System No. 1: Inspiration™ (85 µm)</td>
<td>System No. 2: BioVision™ (50 µm)</td>
</tr>
<tr>
<td>Radiologist 1: 81.0</td>
<td>83.0</td>
<td>82.0</td>
</tr>
<tr>
<td>Radiologist 2: 81.0</td>
<td>82.0</td>
<td>82.0</td>
</tr>
<tr>
<td>Radiologist 3: 81.0</td>
<td>82.0</td>
<td>82.0</td>
</tr>
<tr>
<td>Mean: 81.0</td>
<td>82.3</td>
<td>82.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Magnification</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0:2.0 (No. 1)</td>
<td>System No. 1: Inspiration™ (50 µm)</td>
<td>System No. 2: BioVision™ (70 µm)</td>
</tr>
<tr>
<td>Radiologist 1: 82.0</td>
<td>86.0</td>
<td>87.0</td>
</tr>
<tr>
<td>Radiologist 2: 83.0</td>
<td>86.0</td>
<td>86.0</td>
</tr>
<tr>
<td>Radiologist 3: 84.0</td>
<td>85.0</td>
<td>86.0</td>
</tr>
<tr>
<td>Mean: 83.0</td>
<td>85.6</td>
<td>86.3</td>
</tr>
</tbody>
</table>
topathological diagnosis, re-excision would only have been justified in 5 patients.

The assessment carried out in parallel using CMOS technology (System 2: 2 planes, magnification 1.0:1.0) and SRS technology (System 3: 2 planes, magnification 1.0:1.0) came to approximately the same results (78.6 and 78.3%) compared to the Inspiration™ [System 1] with 78.3% (2 planes, magnification 1.0:1.0), while the figure for tomosynthesis (System 4: 25 projections and cine mode, magnification 1.0:1.0) was significantly (p < 0.05) higher at 86.6% (Table 2).

At magnifications of 1.0:1.5, 1.0:1.4, and 1.0:1.5 respectively (Systems 1–3), the results were 81.0, 82.3 and 82.0%, i.e. they were 2.7, 3.7 and 3.7% higher, but without reaching significance compared to the magnification 1.0:1.0 (Table 2).

At a magnification of 1.0:1.8; 1.0:2.0 and 1.0:2.0 respectively (Systems 1–3), the results were 83.0, 85.6, and 86.3%, i.e. 2.0, 3.3 and 4.3% higher. These differences were not statistically significant when compared to the magnifications 1.0:1.5; 1.0:1.4; and 1.0:1.5; however, at 4.7, 7.0 and 8.0% respectively, they were significantly (p < 0.05) higher when compared to a magnification of 1.0:1.0 (Table 2).

The results for tomosynthesis (System 4) remained unchanged at 86.6% (magnification 1.0:1.0); higher magnifications are not possible for technical reasons.

A retrospective analysis (n=11), i.e. of the re-excisions (two-stage procedure), showed a significant increase (p < 0.05) of sensitivity for the BioVision™ and Trident™ systems and for tomosynthesis of 2.6, 3.3 and 3.6%, respectively, compared to the Inspiration™ at a magnification of 1.0:2.0 and 1.0:1.0 respectively (tomosynthesis). Based on these findings, re-excision would not have been necessary in 2, 3 and 4 patients respectively, compared to the standard magnification of 1.0:1.0 (Table 3) (Figs. 1 to 3).

Discussion

The effectiveness of breast-conserving therapy for the treatment of breast cancer [1–7] can be increased during surgery, i.e. intraoperatively, by the additional use specimen radiography [10–11].

Table 3  Detailed representation of results (R0/R1) (n = 50) for the 4 diagnostic systems (System No. 1: Inspiration™, System No. 2: BioVision™, System No. 3: Trident™, System No. 4: tomosynthesis) at magnifications of 1.0:2.0 and 1.0:1.0 respectively (tomosynthesis), compared to the standard magnification of 1.0:1.0 and the final histological result.

<table>
<thead>
<tr>
<th></th>
<th>n = 50</th>
<th>Histological diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis with the Inspiration™</td>
<td>R0: n = 39</td>
<td></td>
</tr>
<tr>
<td>Diagnosis with the BioVision™</td>
<td>R1: n = 11</td>
<td></td>
</tr>
<tr>
<td>Diagnosis with the Trident™</td>
<td>R1: n = 9</td>
<td></td>
</tr>
<tr>
<td>Diagnosis with tomosynthesis</td>
<td>R1: n = 8</td>
<td></td>
</tr>
<tr>
<td>Diagnosis with tomosynthesis</td>
<td>R1: n = 7</td>
<td></td>
</tr>
</tbody>
</table>

Histology R1: n = 5  R0: n = 6
Intraoperative imaging should be done on 2 planes, where possible, in accordance with the European Guidelines and the S3 Guidelines [8–11]. Radiography could be used to confirm the success of surgical resection intraoperatively. Direct imaging of the resected specimen in 2 planes would permit follow-up resection to be done immediately in cases of incomplete resection. The use of digital imaging plates in combination with conventional analog mammography systems represents a big step forward. These systems use CCD chips with their potential to transfer images to PACS, but the DQE (Detector Quantum Efficiency) is poorer compared to other full digital systems currently in use [14–22]. Over the past 10–15 years imaging systems used exclusively for specimen radiographs have been developed which can be used in different locations (operating room, radiology department, pathology department). Innovations in this field have included the move from conventional systems via the use of imaging plates and full digital systems [14–22] to CMOS technology [23] and tomosynthesis [24]. With the recent use of digital breast tomosynthesis (DBT) [25–32] to complement digital mammography specimen radiography can now be done intraoperatively. In the literature, it was noted that the increase in sensitivity and specificity obtained with tomosynthesis [28] used in addition to digital mammography could reduce recall rates [27,29], also in breast cancer screening of women [32]. In the system we used, specimens were examined radiologically using 25 projections and an angular range of 50 degrees.

Three radiologists assessed the specimen radiographs obtained with the BioVision™ (CMOS technology, 2 planes, System 2), the Trident™ (SRS technology, 2 planes, System 3) using different magnifications (up to 1.0 : 2.0) and tomosynthesis (1 plane, magnification 1.0 : 1.0, both projection images and cine mode images, System 4). Specimen radiographs obtained using the Inspiration™ (2 planes, System 1) were defined as the standard; based on this standard re-excision was done in 11 of 50 patients with histologically proven breast cancer (BI-RADS™ 6) and primary breast-conserving therapy (Table 1).

The BioVision (System 2) and Trident™ (System 3) systems are digital systems used exclusively for specimen radiography. The final histopathological diagnosis of 11 operated patients (re-excision, 2-step procedure) showed that the primary operation was incomplete in 2 patients. However, only 3 patients had safety margins of < 1.0 cm, i.e. with no residual tumor detectable. This means that, based on the final histopathological findings, re-excision was only justified in 5 patients. A retrospective analysis (n = 11) showed a significant increase (p < 0.05) in sensitivity for the BioVision™ and Trident™ systems and for tomosynthesis compared to the Inspiration™ at magnifications of 1.0 : 2.0 and 1.0 : 1.0 (tomosynthesis) respectively. Sensitivity increased by 2.6%, 3.3% and 3.6% respectively, i.e. re-excision would not have been necessary in 2, 3 and 4 patients respectively compared to images obtained using the standard magnification 1.0 : 1.0 (Tables 2, 3) (Figs. 1 to 3).

This may be due to the particularly high resolution of the BioVision™ (focus 0.05, resolution 50 μm pixel pitch, 12 lp/mm) and Trident™ (focus 0.05, resolution 70 μm pixel pitch, 7.1 lp/mm) systems, which were developed exclusively for specimen radiography, and to the principle behind tomosynthesis which allows the texture of breast parenchyma to be characterized very precisely in the mammogram (c − c and obliqu.) [30] as is also evidenced in the specimen radiographs: differentiation is far better (spicules and extent of DCIS compared to benign ductal parenchyma).

In our historical patient cohort and our current retrospective analysis, the re-excision rate after primary breast-conserving therapy (BCT) to treat previously histologically verified breast carcinoma (histological diagnosis: B5 and therefore BI-RADS™ 6) was 22%; the rate in the literature is between 10 and 57%, depending on the definition of the safety margin [12,13]. Our results thus correspond to, or exceed, those obtained using digital specimen radiography, even with the use of zooming [23,33–37]. In conclusion, it should be noted that digital specimen radiography using a magnification of 1.0 : 2.0 and no zooming should be primarily done using systems developed exclusively for specimen radiography or tomosynthesis should be done [37]. Future developments which are expected to improve quality and reduce the rate of re-excisions include the use of 3-D technology in mammographies [38] and the potential use of volumetry based on tomosynthesis [31]. In future, specimen radiography in different planes could be done in the operating room and the images discussed immediately in consultation between the radiologist, surgeon, pathologist using PACS. If a tumorous lesion cannot be unambiguously differentiated from its surrounding tissue, further investigations in addition to ultrasound, for example tomosynthesis, are necessary. Images and findings are then recorded. This mode of procedure would improve the quality and workflows and simultaneously reduce operating times – to the benefit of the patients.

Conflict of Interest

None.

Affiliations

1 Gynäkologische Radiologie, Radiologisches Institut, Universitätsklinikum Erlangen, Erlangen
2 Radiologische Praxis Roth und Weißenburg, Roth
3 Frauenklinik, Universitätsklinikum Erlangen, Erlangen
4 Radiologisches Institut, Universitätsklinikum Erlangen, Erlangen

References


15 Kürrl R, Baltzer J, Lohe KJ. Intraoperative specimen radiography in mammographically suspected, non palpable breast lesions. Experiences with the Faxitron unit. Fortschr Med 1979; 97: 1688–1690


26 Schulz-Wendtland R, Wenkel E. Experimental phantom lesion detectability study using a digital breast tomosynthesis prototype system. Röfo 2006; 178: 1219–1223


38 Schulz-Wendtland R, Bani MR, Lux MP et al. Pilot study on the detection of simulated lesions using a 2D and 3D digital full-field mammography system with a newly developed high resolution detector based on two shifts of a-Se. Geburtsh Frauenheilk 2012; 72: 408–411